RxDoctor Payments Data

Adam Stern, MD

Nephrology · Cary, NCNPI 1376769893

Payments from drug & device makers

$5,704in general payments, 2019–2025

Across 270 payments — averaging $21.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$1K
  • Otsuka America Pharmaceutical, Inc.$927
  • AstraZeneca$539
  • Mallinckrodt Hospital Products Inc.$313
  • Fresenius USA Marketing, Inc.$292
  • Bayer$251
  • plus $2K from 25 others

What the payments were for

  • Food & beverage$5,61198%
  • Education$932%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,704 in reported general payments places this provider in the 70th percentile of 366 nephrology providers in North Carolina.

See all nephrology providers in North Carolina

Medicare billing

Part B allowed, 2024
$202,098
Medicare patients
539
Services billed
1,754

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin90$70,628
FarxigaDapagliflozin Propanediol93$63,900
OzempicSemaglutide18$20,054
LokelmaSodium Zirconium Cyclosilicate13$9,429
JanuviaSitagliptin Phosphate11$6,136
Sevelamer Carbonate20$1,226
Losartan Potassium102$1,041
Febuxostat22$827
Amlodipine Besylate73$760
Famotidine50$599
Calcium Acetate11$560
Carvedilol28$435
Atorvastatin Calcium31$391
Potassium Chloride15$382
Spironolactone54$357

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Lokelma$539$73,329106 claims
Boehringer IngelheimJardiance$65$70,62890 claims
Novo NordiskOzempic$170$20,05418 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 366 nephrology providers in North Carolina.

Other nephrology in Cary

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →